{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:39:54Z","timestamp":1787787594125,"version":"build-2784847793"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Hypofractionation for localized prostate cancer treatment is rapidly spreading in the medical community and it is supported by radiobiological evidences (lower \u03b1\/\u03b2 ratio compared with surrounding tissues). Stereotactic body radiation therapy (SBRT) is a technique to administer high doses with great precision, which is commonly performed with CyberKnife (CK) in prostate cancer treatment. Since the CyberKnife (CK) is not available at all radiotherapy center, alternative SBRT techniques are available such as Volumetric Modulated Arc Therapy (VMAT) and Helical Tomotherapy (HT). The aim of the present study was to compare the dosimetric differences between the CK, VMAT, and HT plans for localized prostate cancer treatment.<\/jats:p>\n            <jats:p>Seventeenpatients have been recruited and replanned using VMAT and HT to this purpose: they received the treatment using the CK with a prescription of 36.25 Gy in 5 fractions; bladder, rectum and penis bulb were considered as organs at risk (OAR). In order to compare the techniques, we considered DVHs, PTV coverage, Conformity Index and new Conformity Index, Homogeneity Index, beam-on time and OARs received dose.<\/jats:p>\n            <jats:p>The 3 treatments methods showed a comparable coverage of the lesion (PTV 95%: 99.8 \u00b1 0.4% CK; 98.5 \u00b1 0.8% VMAT; 99.4\u200a\u00b1\u200a0.5% HT. <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05) and good sparing of OARs. Nevertheless, the beam-on time showed a significant difference (37\u200a\u00b1\u200a9\u200am CK; 7.1\u200a\u00b1\u200a0.3\u200am VMAT; 17\u200a\u00b1\u200a2\u200am HT. <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.05).<\/jats:p>\n            <jats:p>Our results showed that, although CK is the best SBRT technique for prostate cancer treatment, in case this technology is not available, it can be replaced by a similar treatment delivered by VMAT technique. VMAT can be administrated only if it has an appropriate Image Guided Radiation Therapy (IGRT) tracking system.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023574","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T21:56:12Z","timestamp":1607637372000},"page":"e23574","source":"Crossref","is-referenced-by-count":17,"title":["Dosimetric comparison among cyberknife, helical tomotherapy and VMAT for hypofractionated treatment in localized prostate cancer"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7442-7793","authenticated-orcid":false,"given":"Marcello","family":"Serra","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Biomediche Avanzate, Universit\u00e0 degli Studi di Napoli Federico II \u2013 Napoli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Ametrano","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Borzillo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Quarto","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Avanzate, Universit\u00e0 degli Studi di Napoli Federico II \u2013 Napoli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Muto","sequence":"additional","affiliation":[{"name":"Dipartimento Onco-Ematologico Radioterapia, Azienda ospedaliera San Giuseppe Moscati \u2013 Avellino, Italy."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Di Franco","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savino","family":"Federica","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Avanzate, Universit\u00e0 degli Studi di Napoli Federico II \u2013 Napoli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Loffredo","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Biomediche Avanzate, Universit\u00e0 degli Studi di Napoli Federico II \u2013 Napoli"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muto","family":"Paolo","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Istituto Nazionale Tumori - IRCCS - Fondazione G. Pascale - Naples"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"63","DOI":"10.14740\/wjon1191","article-title":"Epidemiology of Prostate Cancer","volume":"10","author":"Rawla","year":"2019","journal-title":"World J Oncol"},{"key":"R2-20230916","first-page":"111","article-title":"Prostate Cancer in Elderly Men","volume":"10","author":"Stangelberger","year":"2008","journal-title":"Rev Urol"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3747\/co.22.2102","article-title":"In 2124, half of all men can count on developing prostate cancer","volume":"22","author":"Pollock","year":"2015","journal-title":"Curr Oncol"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2019.09.020","article-title":"EAU-EANM-ESTRO-ESUR-SIOG prostate cancer guideline panel consensus statements for deferred treatment with curative intent for localised prostate cancer from an international collaborative study (DETECTIVE Study)","volume":"76","author":"Lam","year":"2019","journal-title":"Eur Urol"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3322\/caac.21149","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/0284186X.2012.719635","article-title":"Prostate alpha\/beta revisited - an analysis of clinical results from 14168 patients","volume":"51","author":"Dasu","year":"2012","journal-title":"Acta Oncol"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0360-3016(01)01607-8","article-title":"Is alpha\/beta for prostate tumors really low?","volume":"50","author":"Fowler","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1080\/02841860410002824","article-title":"The radiobiology of prostate cancer including new aspects of fractionated radiotherapy","volume":"44","author":"Fowler","year":"2005","journal-title":"Acta Oncol"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"e12204","DOI":"10.5812\/ijcm.12204","article-title":"Effect of Hypofractionation on Prostate Cancer Radiotherapy","volume":"10","author":"Arabpour","year":"2017","journal-title":"Int J Cancer Manag"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5969 patients in seven international institutional datasets: a\/b\u200a=\u200a1.4 (0.9-2. 2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.clon.2015.02.001","article-title":"The radiobiology of hypofractionation","volume":"27","author":"Nahum","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/S0360-3016(98)00438-6","article-title":"Fractionation and protraction for radiotherapy of prostate carcinoma","volume":"43","author":"Brenner","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1200\/JCO.2005.06.153","article-title":"Randomized trial comparing two fractionation schedules for patients with localized prostate cancer","volume":"23","author":"Lukka","year":"2005","journal-title":"J Clin Oncol"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.ijrobp.2010.07.1984","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial","volume":"81","author":"Yeoh","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"3860","DOI":"10.1200\/JCO.2013.51.1972","article-title":"Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer","volume":"31","author":"Pollack","year":"2013","journal-title":"J Clin Oncol"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2009.07.1691","article-title":"A prospective phase III randomized trial of hypofractionation versus conventional fractionation in patients with high-risk prostate cancer","volume":"78","author":"Arcangeli","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-20230916","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/S1470-2045(15)00567-7","article-title":"Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised non-inferiority phase 3 trial","volume":"17","author":"Aluwini","year":"2016","journal-title":"Lancet Oncol"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1177\/153303461000900605","article-title":"Stereotactic body radiotherapy for organ-confined prostate cancer","volume":"9","author":"Katz","year":"2010","journal-title":"Technol Cancer Res Treat"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/153303460900800509","article-title":"Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer","volume":"8","author":"Friedland","year":"2009","journal-title":"Technol Cancer Res Treat"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1748-717X-6-3","article-title":"Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes","volume":"6","author":"Freeman","year":"2011","journal-title":"Radiat Oncol"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1748-717X-8-171","article-title":"Linac based SBRT for prostate cancer in 5 fractions with VMAT and flattening filter free beams: Preliminary report of a phase II study","volume":"8","author":"Alongi","year":"2013","journal-title":"Radiat Oncol"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.semradonc.2008.04.001","article-title":"An overview of hypofractionation and introduction to this issue of seminars in radiation oncology","volume":"18","author":"Timmerman","year":"2008","journal-title":"Semin Radiat Oncol"},{"key":"R26-20230916","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1120\/jacmp.v12i2.3368","article-title":"Dose tolerance limits and dose volume histogram evaluation for stereotactic body radiotherapy","volume":"12","author":"Grimm","year":"2011","journal-title":"J Appl Clin Med Phys"},{"key":"R27-20230916","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2016.08.005","article-title":"Extreme hypofractionation for early prostate cancer: biology meets technology","volume":"50","author":"De Bari","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"R28-20230916","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1586\/14737140.2014.883282","article-title":"From radiobiology to technology: what is changing in radiotherapy for prostate cancer","volume":"14","author":"De Bari","year":"2014","journal-title":"Expert Rev Anticancer Ther"},{"key":"R29-20230916","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1177\/1533034616682156","article-title":"Dosimetric comparison and evaluation of 4 stereotactic body radiotherapy techniques for the retreatment of prostate cancer","volume":"16","author":"Sepp\u00e4l\u00e4","year":"2017","journal-title":"Technol Cancer Res Treatment"},{"key":"R30-20230916","first-page":"465","article-title":"Dosimetric and radiobiological comparison of Cyberknife and Tomotherapy in stereotactic body radiotherapy for localized prostate cancer","volume":"25","author":"Chun","year":"2017","journal-title":"J Xray Sci Technol"},{"key":"R31-20230916","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.clon.2013.08.008","article-title":"Stereotactic body radiotherapy in prostate cancer: is rapidarc a better solution than CyberKnife?","volume":"26","author":"MacDougall","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"R32-20230916","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.rpor.2014.10.010","article-title":"Integral dose: Comparison between four techniques for prostate radiotherapy","volume":"20","author":"Slosarek","year":"2014","journal-title":"Rep Pract Oncol Radiother"},{"key":"R33-20230916","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ejmp.2014.03.008","article-title":"Treatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: Non-isocentric CyberKnife versus isocentric RapidArc","volume":"30","author":"Lin","year":"2014","journal-title":"Phys Med"},{"key":"R34-20230916","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijrobp.2009.07.1752","article-title":"Dose gradient near target-normal structure interface for nonisocentric CyberKnife and isocentric intensity-modulated body radiotherapy for prostate cancer","volume":"78","author":"Hossain","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023574","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T04:08:58Z","timestamp":1694837338000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":33,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023574","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}